Fig. 4From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in JapanKaplan-Meier curves of overall survival (OS) in mRCC patients treated with sorafenib plus IFN-α. The median OS has not been reached yetBack to article page